TX-MARY-KAY-INC
Mary Kay Inc., a global advocate for corporate social responsibility, today released a report detailing progress on Enriching Lives Today for a Sustainable Tomorrow (ELTFAST), the brand’s global sustainability program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005001/en/
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay's vision to 2030 and beyond. (Credit: Mary Kay Inc.)
“We’re proud of the progress we’ve made on our sustainability journey so far, and we are inspired to see how our actions today will address global challenges for future generations,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay has operations in nearly 35 countries—we consider that an accomplishment and a responsibility. Enriching Lives Today for a Sustainable Tomorrow is our roadmap for supporting our business strategy, reducing our environmental impact, and supporting communities where we operate.”
Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay’s vision to 2030 and beyond. It builds a picture of what good “looks like” for Mary Kay, Independent Beauty Consultants, customers and—most importantly—the planet. Enriching Lives Today for a Sustainable Tomorrow was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay a key part of a global coalition to ensure a better future.
The 2020 – 2022 full report can be viewed here. An executive summary of the report is available here.
Since the launch of ELTFAST in 2020, Mary Kay has made significant progress toward its goals despite the many challenges presented by the COVID-19 epidemic. The 2022 report details its efforts since 2020—the beginning of its Decade of Action—and serves as a reaffirmation of the company’s drive to deliver sustainable change.
Business Excellence
- Focusing on nurturing its company culture, Mary Kay garnered 13 employer / great place to work awards and was ranked #8 on list of “The Companies Employees Don’t Want to Leave,” published by Resume.io.
- Released gender diversity data in leadership: executive team is 54% female, managers and above are 59% female, with 62% of the total workforce being female.
- In 2021, scored 75% employee engagement, a 6% increase over the 2019 full engagement survey (This is 10% over the global average for employee engagement).
- 38 company awards in business excellence, social impact, and sustainability.
-
Deloitte named Mary Kay Inc. one of the 2022 U.S. Best Managed Companies.
Product Stewardship
- Achieved Forest Stewardship Council (FSC) certification (U.S.A only). The FSC certification ensures products come from responsibly managed forests providing environmental, social and economic benefits.
- 12% of our indirect suppliers are women, minority or veteran-owned (U.S.A. only).
- Achieved palm oil–88% certified and palm kernel–72% certified.
- Held inaugural Sustainability-Focused Supplier Summit at global headquarters.
- Named 2022 Silver Champion for Supplier Diversity & Inclusion.
-
Nominated and approved member of the steering committee for SPICE (Sustainable Packaging Initiative for CosmEtics).
Responsible Manufacturing
- Supported The Arbor Day Foundation on three global reforestation projects in Brazil, Madagascar, and the United States.
- Continued additional water usage analysis with plans to install new water flow meters.
- Supported The Nature Conservancy’s Global Reefs program through 12 unique impact programs.
- Joined the UN Global Compact’s Ocean Stewardship Coalition.
- Richard R. Rogers Manufacturing/R&D facility (R3), announced it passed its OSHA VPP Star Re-Certification with zero findings and recommendations.
- Received OSHA Star Re-Certification Credentials.
Women’s Empowerment
- Published “Piloting SDG Localization at the Village Level: A Women-focused Poverty Reduction and Sustainable Development Project in Yunnan Province, China.” Impact Report (Phase 1: 2017-2021).
- Completed The Women’s Empowerment Principles Gender Gap Analysis Tool as part of our participation in the UN Global Compact Target Gender Equality Accelerator.
- Advanced women’s leadership in the fishing industry in Mexico through eight projects implemented by The Nature Conservancy.
- Powered the global launch of a free Entrepreneurship Program in six languages, developed by International Trade Centre SheTrades Initiative.
- Awarded 14 STEAM grants to young women around the world pursuing dreams in STEAM-related industries.
- Joined the UN Global Compact Target Gender Equality Program to deepen implementation of the Women’s Empowerment Principles.
- Submitted survey on the implementation of commitments across the Generation Equality Action Coalitions; findings reflected in UN Women’s Generation Equality Accountability Report 2022.
Social Impact
- Since 2008, Pink Changing Lives has impacted more than six million women and their families by partnering with over 3,250 organizations and donating over $17 million. In 2022, the cause empowerment program supported over 20 NGOs around the world.
- Mary Kay and the Mary Kay Ash Foundation grants supported the development and launch of a “GBV Guidance for Development Programs” and its rollout in 10 countries of intervention as well as the establishment of a Community of Practice convening 240 members across 16 countries to date.
- Mary Kay and the Mary Kay Ash Foundation grants helped the UN Trust Fund change the lives of 54,822 women and girl survivors of violence through 157 GBV projects in 68 countries across five regions including women and girls living with disabilities, internally displaced or refugee women and girls, and Indigenous women and girls.
- Donated more than $1.3 million to global organizations helping to enrich women’s lives.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
